Rivaroxaban

Rivaroxaban is a highly selective direct Factor Xa inhibitor used as an oral anticoagulant to prevent and treat various thromboembolic disorders, including deep vein thrombosis and stroke in patients with atrial fibrillation.

The dosage of rivaroxaban varies significantly depending on the condition being treated. It is imperative to follow the specific regimen prescribed by your healthcare provider.

• Non-Valvular Atrial Fibrillation: The standard dose is typically 20 mg once daily, taken with the evening meal. For patients with moderate renal impairment, the dose may be reduced to 15 mg once daily.
• Treatment of DVT and PE: The initial treatment usually begins with 15 mg taken twice daily with food for the first 21 days. This is followed by a maintenance dose of 20 mg once daily with food for the remainder of the treatment duration.
• Reduction in Risk of Recurrence of DVT/PE: After at least 6 months of initial treatment, a dose of 10 mg once daily (with or without food) may be considered by your physician.
• DVT Prophylaxis (Post-Surgery): For hip replacement, 10 mg once daily for 35 days. For knee replacement, 10 mg once daily for 12 days. These doses can be taken with or without food.
• CAD and PAD: The standard dose is 2.5 mg taken twice daily, in combination with a daily low-dose aspirin (75-100 mg). This can be taken with or without food.

Rivaroxaban is approved for use in pediatric patients from birth to less than 18 years of age for the treatment of venous thromboembolism (VTE) and to reduce the risk of VTE recurrence. Dosing in children is weight-based and typically administered as an oral suspension or tablets. For example, children weighing more than 50 kg may receive the adult 20 mg dose, while smaller children receive lower, precisely calculated doses. Pediatric dosing should only be managed by a specialist familiar with pediatric anticoagulation.

Renal Impairment

Because a significant portion of rivaroxaban is cleared by the kidneys, dosage adjustments are necessary for patients with decreased kidney function. Healthcare providers use the Creatinine Clearance (CrCl) rate to determine the appropriate dose. For patients with a CrCl between 15 and 50 mL/min, the dose for atrial fibrillation is usually reduced to 15 mg. Use is generally avoided in patients with a CrCl of less than 15 mL/min.

Hepatic Impairment

Rivaroxaban is not recommended for patients with moderate to severe hepatic (liver) impairment (Child-Pugh B or C) or any liver disease associated with coagulopathy (a condition where the blood's ability to clot is impaired), as this significantly increases the risk of life-threatening bleeding.

Elderly Patients

While no specific dose adjustment is required based solely on age, elderly patients are more likely to have reduced renal function and a higher risk of bleeding. Clinical monitoring is essential in this population.

1. 1Consistency: Take your medication at the same time every day to maintain steady levels in your blood.
2. 2Food Requirements: The 15 mg and 20 mg tablets must be taken with food. The 2.5 mg and 10 mg tablets may be taken with or without food.
3. 3Swallowing: Tablets should be swallowed whole. For patients who cannot swallow tablets, the 10 mg, 15 mg, and 20 mg tablets may be crushed and mixed with applesauce immediately before administration. If using this method, the dose should be followed immediately by food.
4. 4Storage: Store the medication at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place.

If you miss a dose of rivaroxaban:

• For once-daily dosing: Take the missed dose as soon as you remember on the same day. If it is the next day, skip the missed dose and take your next dose at the regular time. Do not take two doses at once to make up for a missed one.
• For 15 mg twice-daily dosing: Take the missed dose immediately to ensure you receive 30 mg total for the day. You may take two 15 mg tablets at the same time if necessary.

An overdose of rivaroxaban increases the risk of severe, potentially fatal bleeding. Signs of an overdose include unusual bruising, red or black stools, pink or brown urine, or coughing up blood. In the event of an overdose, seek emergency medical attention immediately. A specific reversal agent, Andexanet alfa (Andexxa), is available in hospital settings to neutralize the effects of rivaroxaban in life-threatening situations.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as stopping abruptly increases your risk of a stroke or blood clot.

The most common side effect of rivaroxaban is bleeding, which occurs because the medication reduces the blood's ability to clot. This can manifest in several ways:

• Increased tendency to bruise: You may notice bruises appearing more easily or from minor bumps.
• Nosebleeds (Epistaxis): These may occur more frequently and take longer to stop.
• Bleeding gums: Especially after brushing or flossing teeth.
• Prolonged bleeding from cuts: Minor injuries may require more pressure and time to stop bleeding.

Other common non-bleeding side effects include:

• Dizziness or Lightheadedness

Rivaroxaban is a high-alert medication because of its potential to cause significant bleeding. It is vital to inform every healthcare provider you visit—including dentists, surgeons, and pharmacists—that you are taking rivaroxaban. You should carry a medical alert card or wear a medical alert bracelet at all times.

As detailed in the side effects section, the FDA mandates two primary Black Box Warnings for rivaroxaban. The first warns that stopping the drug prematurely increases the risk of stroke. The second warns of the risk of spinal or epidural hematomas in patients undergoing spinal procedures. These are the most serious warnings the FDA issues, and they must be discussed thoroughly with your physician.

• Bleeding Risk: Rivaroxaban increases the risk of bleeding and can cause serious or even fatal bleeding. Risk factors include older age, renal impairment, and the use of other medications that increase bleeding (such as aspirin, clopidogrel, or NSAIDs like ibuprofen).

Certain medications significantly increase the levels of rivaroxaban in the blood, leading to an unacceptable risk of bleeding. These include:

• Strong Dual Inhibitors of CYP3A4 and P-gp: Medications such as ketoconazole, ritonavir, lopinavir, and conivaptan. These drugs block both the primary enzyme that breaks down rivaroxaban and the 'pump' (P-glycoprotein) that removes it from the body. Using these together can more than double the amount of rivaroxaban in your system.

• Other Anticoagulants: Using rivaroxaban with heparin, warfarin, or other DOACs (like apixaban) is generally avoided except when switching between therapies, as it massively increases bleeding risk.
• Antiplatelet Agents: Drugs like clopidogrel, prasugrel, and ticagrelor increase the risk of bleeding. While sometimes used together in CAD/PAD, this requires careful medical supervision.

Rivaroxaban must NEVER be used in the following circumstances:

1. 1Active Pathological Bleeding: Patients with current major bleeding, such as a gastrointestinal ulcer, intracranial hemorrhage, or any other condition where bleeding is not controlled, must not take rivaroxaban. The drug's mechanism of action prevents the body from forming the clots necessary to stop the bleed.
2. 2Severe Hypersensitivity: If you have had a documented severe allergic reaction (such as anaphylaxis or Stevens-Johnson Syndrome) to rivaroxaban or any of its inactive ingredients, you cannot take this medication.
3. 3Severe Renal Impairment (CrCl < 15 mL/min): In patients with end-stage renal disease or those on dialysis, the clearance of the drug is so unpredictable that the risk of fatal bleeding outweighs the benefits.

Rivaroxaban is classified under a category where data in pregnant women are limited. However, based on its mechanism of action and animal studies, there is a significant risk of pregnancy-related hemorrhage for both the mother and the fetus. It may also increase the risk of pregnancy loss. Use during pregnancy is generally avoided unless the potential benefit justifies the potential risk to the fetus. If you become pregnant while taking rivaroxaban, notify your doctor immediately. Most guidelines recommend switching to low-molecular-weight heparin (LMWH) during pregnancy.

Studies indicate that rivaroxaban is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants—specifically the risk of bleeding—a decision must be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Most healthcare providers recommend avoiding breastfeeding while on rivaroxaban.

Rivaroxaban is approved for pediatric use for the treatment and prevention of VTE. The safety and effectiveness have been established in children from birth to 18 years. Dosing is strictly weight-based. However, it is not approved for children with certain conditions, such as those with prosthetic heart valves or those with significant renal or hepatic impairment. Pediatric patients must be monitored closely for signs of bleeding, especially during growth spurts when dose adjustments may be necessary.

Rivaroxaban is a highly selective, direct inhibitor of Factor Xa. It does not require a cofactor (like Antithrombin III) to exert its effect, which distinguishes it from indirect inhibitors like heparin. By binding to the S1 and S4 pockets of the Factor Xa enzyme, it prevents the enzyme from cleaving prothrombin into thrombin. This inhibition is reversible and competitive. Because Factor Xa sits at the convergence of the intrinsic and extrinsic pathways of the coagulation cascade, its inhibition is a highly efficient way to dampen the entire process of thrombus formation.

The inhibition of Factor Xa activity is dose-dependent. Rivaroxaban also affects clotting tests like Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT), but these changes are highly variable and are not used to monitor the drug's effect in clinical practice. The maximum effect on Factor Xa inhibition occurs approximately 2 to 4 hours after taking a tablet, coinciding with peak plasma concentrations.

| Parameter | Value |

|---|---|